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ABSTRACT 
Cutaneous Tuberculosis is also known as dermal tuberculosis or tuberculosis cutis (extrapulmonary tuberculosis) which can occur in 
any age group and patients who may or may not be suffering from pulmonary tuberculosis. The current treatment given for the 
disease is oral therapy of anti-tubercular drugs which has many side effects such as hepatotoxicity, headache, anxiety, euphoria, 
insomnia, eosinophilia, hepatitis. Hence to avoid these side effects and to increase efficiency of current therapy a topical 
proniosomal gel of isoniazid was formulated. Coacervation phase separation method was used and proniosomal gel was formulated 
by using Span 20, soya lecithin, and cholesterol. Optimum concentration of 3 factors Span 20, soya lecithin, and cholesterol were 
determined using Box Behnken design with at 2 levels and vesicle size and entrapment efficiency as responses. The optimized 
proniosomal gel was characterized by vesicle size, entrapment efficiency, transmission electron microscopy (TEM), in vitro drug 
release, skin retention studies, skin irritation studies and stability studies. The optimised batch showed vesicle size of 2.27±1.82 µ, 
and entrapment efficiency of 98.15±0.25 %. The optimised formulation was stable under refrigeration condition (5°C) in amber 
coloured bottle, was non-irritating and showed 98.10±1.28 % release and 85±1.53 % permeation after 6 h and 436±12 µg drug was 
retained in the skin after 3 hrs. 
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INTRODUCTION 
Mycobacterium tuberculosis is a worldwide 
problematic, communicable pathogen causing both 
pulmonary as well as skin tuberculosis. Cutaneous 
tuberculosis (CTB) also known as dermal tuberculosis 
or tuberculosis cutis refers to pathological lesions of the 
skin caused by any one of the following: 
Mycobacterium tuberculosis, Mycobacterium bovis or 
the BCG vaccine
1
. Most often CTB is an airborne 
transmissible disease with skin manifestations 
presenting as a result of haematogenous spread or direct 
extension from latent or active foci of infection. 
However, primary inoculation may occur as a direct 
introduction of the mycobacterium into the skin or 
mucosa of a susceptible individual by trauma or injury. 
Drug addicts and patients suffering from AIDS, 
diabetes, malignancies and end stage renal disorders are 
at high risk of acquiring this disease 
2
. CTB is frequently 
misleading as it mimics a wide differential diagnosis 
and also evades microbiological confirmation despite 
recent advances in sophisticated techniques. Although 
rare (0.7% worldwide) it is important for clinicians to 
recognize the many clinical variants of CTB to prevent 
missed or delayed diagnoses. 
CTB is treated with a combination of rifampicin, 
ethambutol, pyrazinamide, isoniazid and streptomycin 
that is tailored to individual needs 
3
. Currently the 
treatment given for the CTB is the same as that for 
pulmonary TB and consists of long term two phase 
multidrug therapy i.e. isoniazid, rifampicin, ethambutol 
and pyrazinamide for 2 months in initial phase and then 
isoniazid and rifampicin for the next 4 months as second 
phase of treatment 
2, 4
. The antitubercular drugs 
(isoniazid, rifampicin, ethambutol and pyrazinamide) 
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are administered until complete clearance of the 
condition is seen. The drawback of oral antitubercular 
therapy includes adverse effects in the patient such as 
insomnia, eosinophilia, hepatitis, hepatotoxicity, 
peripheral neuropathy, psychosis, seizures, toxic 
encephalopathy or coma. Hence a topical preparation is 
required to overcome the drawbacks of current therapy 
and provide an efficacious treatment to patient
 5
 No 
current topical treatment for CTB has been found in the 
literature. Although topical therapy would not be a 
substitute for conventional treatments, it may be used 
concurrently and possibly aid in improving treatment 
outcomes 
3
. 
Isoniazid (INH) is a first line antitubercular drug for the 
treatment of pulmonary as well as cutaneous 
tuberculosis. It is white crystalline powder, odourless 
and slowly affected by exposure to air and light. INH 
gets converted to isonicotinic acid due to radical-
mediated chain reaction (Bhutani et al).It comes under 
borderline of BCS Class I and Class III drugs with good 
aqueous solubility of (140000 mg/L at 25°C), Log P -
0.71(hansch, ceta1995) and pKa of 1.82 at 20°C(Perrin, 
DD 1965). It is a bactericidal drug and acts by inhibiting 
biosynthesis of mycolic acid which is major component 
of bacterial cell wall
 6
. The drug faces various stability 
problems like hydrolysis, oxidation and photolysis, 
forming isonicotinic acid and isonicotinamide. INH is 
stable to dry heat at 50-60°C whereas degradation is 
increased in presence of metal ions like Cu, Mg etc.
7
. 
Proniosomal gel (PNG) preparations are semisolid 
liquid crystal products of non-ionic surfactants prepared 
by dissolving the surfactant in a minimum amount of 
organic solvent and aqueous phase
 9
. PNG offers a great 
potential to reduce the side effects of drugs and increase 
therapeutic effectiveness. These can entrap both 
hydrophilic and hydrophobic drugs
10
. Liposomes are 
formulated using lipids which may cause vesicle 
instability. Niosomes are more prone to oxidation and 
hydrolysis as it consists of greater proportion of aqueous 
solvent as compared to proniosomal gel. PNG was better 
candidate for formulating INH topical preparation as it 
consists of non-ionic surfactant which stabilises vesicles 
and contains very less amount of aqueous solvent. 
Hence PNG was selected as it is reported to prevent 
hydrolysis and oxidation of encapsulated drug
11
. PNG 
show controlled and sustained release of drugs due to 
depot formation. These formulations are biodegradable, 
biocompatible and non-immunogenic to the body
12
. 
The aim of the present study was to develop a topical 
formulation which would be effective against CTB as 
well as overcome the drawbacks of current oral therapy. 
The PNG formulationwas prepared by coacervation 
phase separation method reported by Perret et al with 
some modifications. Theformulation was optimised by 
Box Behnken design with 3 factors at 2 levels using 
Design Expert software version 11. The formulations 
were further evaluated for its vesicle size, entrapment 
efficiency (EE), viscosity, spreadability, skin retention, 
skin permeation, skin irritation and stability. 
 
MATERIALS AND METHODS 
Materials: 
INH was gifted by Amsal Pharmaceuticals Pvt. Ltd, 
Mumbai, India. Soya lecithin (SL), cholesterol, Span 20 
was purchased from S.D. Fine Pvt. Ltd Mumbai. 
Methanol (AR grade) was purchased from Loba 
chemicals, Mumbai. All other chemicals and reagents 
used were of analytical grade. 
Methods: 
Characterisation of Drug: 
The thermal behaviour of drug was checked by 
differential scanning calorimeter (Make: Mettler Toledo 
DSC, Model: 823e).Characterisation of drug was also 
done by fourier transfer infrared spectroscopy (FT-IR) 
(Make: Brukers alpha, Software: Opus) of INH was 
performed. 
High Performance Liquid Chromatography (HPLC) 
analytical method: 
Weighed quantity of drug was dissolved in Distilled 
Water (DW) (HPLC grade) to obtain 1000µg/mL 
solution. From this stock solution 5, 10,15,20,25 µg/mL 
solutions were prepared and analysed by RP HPLC 
(Make: Agilent, Model: 1120 Compact LC) equipped 
with EZ- Chrome Elite software with UV detector set at 
263nm. The areas of the dilutions were observed and 
plotted against concentration (Fig 2). The mobile phase 
used was according to IP 
13 
with some modifications. 
The mobile phase was prepared by dissolving 1.4 g 
disodium hydrogen phosphate and 1 mL of 
trimethylamine in 1000 mL with DW (HPLC grade). 
The pH was adjusted 6.0 with orthophosphoric acid and 
mixed with acetonitrile in the ratio of 90:10. The sample 
(20µl) was injected in the loop injector with flow rate of 
1 mL/min and the column used was C18 (Make: Agilent 
TC C18 (250 mm x 4.6 mm i.d., 5 μm particle size). The 
method was validated for linearity (5-25µg/mL), 
precision (interday and intraday), accuracy, limit of 
detection (LOD), limit of quantification (LOQ). 
Drug Excipient compatibility studies:    
The drug and potential excipients were kept in 1:1 ratio 
at 5°C in refrigerator (Make: Bluestar) in amber 
coloured vials to check any reaction which may take 
place between drug and excipients. The samples were 
analysed by FT-IR after 1 month along with standard 
drug and excipients as the reference. 
Preliminary Stability Testing: 
Preliminary stability studies were conducted in two 
stages according to ICH
14
 guidelines as follows: 
Solution state stability:  
INH (10mg) was dissolved in 10 mL of DW and kept at 
accelerated conditions (40°C/75 % RH), room 
temperature (RT) (30°C/65 % RH), refrigeration 
conditions (5°C) in stability chamber (Make: 
Thermolab, Model: TH 200S) in amber coloured vials 
for 1 month. The solutions were analysed for drug 
content by HPLC (Table 1) 
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Table 1: Layout of excipients for selection of surfactant 
Batch Span 20 
(mg) 
Span 60 Span 80 SL Cholesterol 
(mg) 
Ethanol 0.1% glycerol 
solution 
B1 450 - - 50 50 0.25 0.8 
B2 - 450 - 50 50 0.25 0.8 
B3 - - 450 50 50 0.25 0.8 
 
Solid state stability: 
Solid INH was kept at RT and refrigeration conditions 
in amber coloured vial for 1 month. The samples were 
subjected to FT-IR studies and drug content. 
Stability in cream formulation: 
The INH o/w cream was formulated with excipients 
such as white petrolatum (5g), cetostearyl alcohol (5g), 
propylene glycol (2.4g), tween 80 (0.2g) and DW 
(17.4mL)
 15
. The cream was prepared by mixing oil 
phase (white petrolatum, cetosteryl alcohol, and 
propylene glycol) and aqueous phase (water, tween 80, 
drug) when both the solutions acquired same 
temperature (70°C) while continuous stirring at 
mechanical stirrer for 10 min at 800 rpm to obtain white 
homogenised cream. The cream was analysed to check 
if the drug remains stable in the formulation as no 
reported data was obtained regarding topical formulation 
of INH. The cream was stored at accelerated conditions, 
RT in stability chamber and refrigeration for 1 month in 
amber coloured wide mouth bottle. The formulation was 
evaluated for drug content at an interval of 7 days by 
HPLC. 
Stability in INH plain gel: 
The INH plain gel was formulated with excipients such 
as Carbopol 934 (0.1 g), glycerine (0.5 g), propylene 
glycol (1 g) and DW (3.348 mL) 
16
. The gel was 
prepared by adding a hot mixture (60-70°C) of 
propylene glycol, glycerine and drug into a beaker 
containing carbopol 934 and warm water. The gel was 
analysed to check if the drug remains stable in the 
formulation. Based on the results obtained from the drug 
content of the cream formulation, the gel was stored at 
RT in stability chamber and refrigerationfor 1 month in 
amber coloured bottle. The formulation was evaluated 
for drug content at an interval of 7 days by HPLC. 
Stability in Proniosomes: 
The INH proniosomes were prepared with cholesterol, 
SL and different surfactants like Span 20, Span 60 and 
Span 80 singly. Required quantities of surfactant, 
cholesterol and SL were mixed with ethanol in a beaker. 
Beaker was covered to prevent loss of solvent and the 
mixture was heated in a water bath (Make: Metalab) at 
30-40°C for 10 min until surfactant dissolved 
completely. To this, 0.1% aqueous glycerol solution was 
added and heated again at 30-40°C for 10 min
17
. Then 
mixture was allowed to cool to RT. The proniosomes 
were checked for drugs stability in the formulation. The 
proniosomes were stored at RT in stability chamber and 
refrigeration for 1 month in amber coloured wide mouth 
bottle. The formulation was evaluated for drug content 
at an interval of 7 days by HPLC. 
Preliminary studies: 
Selection of surfactant: 
Blank proniosomes were prepared with similar 
procedure as mentioned above without adding drug 
(Table 1).The proniosomes were analysed for vesicle 
size and polydispersity index (PDI) by Zeta Sizer 
(Make: Malvern, Model: nano Zs-90) by diluting 0.1g of 
blank proniosomes with glycerine. The surfactant 
producing least vesicle size and PDI was selected for 
further studies. 
Experimental Design: 
Based on results of preliminary studies, the Box-
Behnken experimental design was selected to 
investigate the effect of 3 independent variables at 2 
levels on responses. These variables included 
concentration of Span 20 (A), cholesterol (B) and SL 
(C) with vesicle size (Y1) and EE (Y2) as responses. 
The 2 levels (Table 2) of Span 20 (A) in the formulation 
were varied from 0.9 and 3.6, while levels of cholesterol 
(B) varied were 0.1 and 0.4 g and levels of SL (C) 
varied were 0.1 and 0.4 g. Based on 2 levels and one 
centre point given by the software, fifteen trial batches 
(R1-R15) were generated by Design Expert software 
(Design Expert 10, Stat-Ease, Minneapolis, MN) (Table 
3). Optimized batch was selected from solutions given 
by software on the basis of constraints provided to 
software and 3D response curves for both the responses. 
The responses of all the 15 runs were fitted in the 
quadratic polynomial model. The appropriate fitting 
model for each response was selected based on the 
difference of numerous statistical parameters such as R
2
, 
sequential model sum of squares and partial sum of 
square given by the analysis of variance (ANOVA). The 
optimised batch of proniosomes so obtained was added 
into the Carbopol 934 gel (5%) in the ratio 3:0.5 to 
obtain optimised 1% INH PNG. 
 
Table 2: Box-Behnken design layout for optimization of proniosomes. 
Factors Levels Responses 
-1 0 +1 
Factor A: Span 20 (g) 0.9 2.25 3.6 % Entrapment efficiency 
and 
vesicle size 
Factor B: Cholesterol (g) 0.1 0.25 0.4 
Factor C: SL (g) 0.1 0.25 0.4 
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Evaluation of optimisation batches of proniosomes: 
Vesicle Size: 
The vesicle size of the proniosomal gel prepared was 
measured by Zeta Sizer. Proniosomes (0.1 g) were taken 
and diluted with glycerine and analysed for vesicle size 
19, 20
. 
Entrapment efficiency (EE): 
In a glass tube weighed (Make: Shimadzu, Model: AW 
220) quantity of proniosomes (0.1g) were taken and 
made up the volume up to 10 mL with phosphate buffer 
pH 5.5 
23
. The solution was centrifuged at 6,000 rpm at 
30°C for 90 min in an ultra-centrifuge (Make: Remi, 
Model: RM-12C BL). The supernatant was assayed by 
validated HPLC method 
21, 22
. The percentage of drug 
entrapped (EE (%)) was calculated by the following Eq. 
1: 
                     
 
                                    
                    
     
Evaluation of Proniosomes: 
The factorial batches were analysed for vesicle size and 
EE and the optimised batch of proniosomes was 
analysed for optical microscopy at 40X, zeta potential 
(ZP) 
18
 and optimised PNG was evaluated for pH, 
spreadability, viscosity, in vitro release, ex vivo 
permeation, skin irritation, in vitro retention, and 
stability studies. 
Evaluation of optimisedproniosomal gel 
Determination of pH: 
The pH of the optimised PNG was determined by a 
digital pH meter (Make: Deluxe pH meter, Model: 
Deluxe 101). Optimised PNG (1 g) was dissolved in 20 
mL of DW and the electrode was then dipped into gel 
formulation and constant reading was noted. The 
measurements of pH of formulation were replicated 
three times 
24
. 
Determination of viscosity: 
The viscosity determination of the formulation is 
important as it affects spreadability of the formulation 
and in turn its performance 
25
. Brookfield digital 
viscometer (Make: Brookfield, Model: DV II + Pro 
viscometer) was used for the viscosity determination. 
The quantity of 100 g of optimised PNG was taken in a 
beaker, spindle S 07 was dipped into it and the viscosity 
in centipoises (cp) was measured at 20 rpm after 30 sec 
at ambient temperature and in triplicate. The % torque 
(τ) was in the range of 10-100 %. 
Spreadabiliy: 
The spreadability of PNG was determined by using 
Texture Analyser (Make: Brookfield, Model: CT 100). 
Optimised PNG (20 g) was taken in the cup of the 
texture analyser, previously aligned with the probe 
(TA3/100). The trigger load was 0.5 g and test speed 
was 1 mm/sec. The hardness value obtained was 
recorded 
26
. 
 
Determination of drug content: 
Optimised PNG (0.1 g) was accurately weighed and 
diluted to 10mL with DW and vortexed (Make: Remi 
Laboratories CM101) to produce stock solution. From 
this stock solution 1 mL of the solution was taken and 
was further diluted to 10 mL with mobile phase (same 
as given above for HPLC analytical method). The 
solution was filtered using Whatman filter paper (0.45 
µm) and HPLC analysis was conducted
27
. 
In vitro release studies and ex vivo skin permeation 
studies: 
In vitro release studies of optimised PNG formulation 
was performed by Franz diffusion cell (Make: Orchid 
Scientifics Model: FDC03) using cellophane membrane 
previously soaked in phosphate buffer pH 5.5 
24
 for 24 
h. The cellophane membrane (Make: Pal life sciences 
ltd. pore size=0.45µm) was mounted between the donor 
and receptor compartment both containing phosphate 
buffer pH 5.5. Weighed quantity of optimised PNG (0.3 
g containing 4.4 mg of drug) was applied on donor side 
of the cellophane membrane. The assembly was 
maintained at 37±1°C with constant stirring using 
magnetic beads. At sampling intervals of 30 min for 6 h, 
1 mL sample was withdrawn and replaced by equal 
volumes of fresh medium to maintain sink condition. 
The samples were diluted to10 mL with phosphate 
buffer pH 5.5 and filtered using Whatman filter paper 
(0.45 µm) and analyzed by HPLC
28, 29
. 
Ex vivo skin permeation studies were performed using 
same procedure and analytical method as used for in 
vitrorelease studies. The cellophane membrane was 
replaced with subcutaneous skin of male albino Wistar 
rats with diffusion area of 2.26 cm
2
.The skin was 
properly cleaned to remove the subcutaneous fat and 
other blood vessels.The cumulative amount of drug 
permeated across the rat skin was calculated and plotted 
against time and the flux was calculated as drug 
permeated per cm
2
 per hour 
30
. 
In vivo skin irritation studies: 
Protocol approved by institutional animal ethics 
committee with approval no: CPCSEA/IAEC/PT-01/01-
2K18 at AISSMS College of pharmacy. The albino 
Wistar rats were housed in polypropylene cages, with 
free access to standard laboratory diet and water. 
Animals were acclimatized for at least 7 days before 
experimentation. The dorsal abdominal skin of rats was 
depilated (approx. 10 cm
2
) 24 h before study. Optimised 
PNG was applied and site of application was covered 
with a non sensitizing microporous tapes. Formalin (0.8 
% w/v) solution was applied as standard skin irritant. 
Blank PNG was applied as placebo. After washing the 
applied gel, the resulting reaction was evaluated by 
visual observation of the skin for any change such as 
erythema at 24, 48 and 72 h after the application of the 
formulations. The mean erythemal scores were recorded 
(ranging from 0-4), depending on the degree of 
erythema, as follows: no erythema=0; slight erythema 
(barely perceptible-light pink) =1; moderate erythema 
(dark pink) =2; moderate to severe erythema (light red) 
=3; and severe erythema (extreme redness) =4 grade
31
. 
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Skin retention studies: 
Protocol approved by institutional animal ethics 
committee with approval no: CPCSEA/IAEC/PT-
0+1/01-2K18 AISSMS College of Pharmacy. The 
optimised PNG was applied to the depilated skin of the 
male albino Wistar rats, and after a predetermined time 
interval (3 h), the animals were euthanized and the skin 
was surgically removed for analysis of drug retained in 
the skin. For drug analysis, the skin was cut into small 
pieces and then vortexed in methanol for drug 
extraction. The skin tissue was also homogenized by 
using a homogenizer (Make: Biolab instruments Model: 
BL244). Drug quantification was performed by using 
validated HPLC method 
32
. 
Stability studies: 
The optimised PNG formulation was analysed for 
stability studies according to ICH guidelines (Q1A(R2)) 
14
. The optimised PNG was stored at RT as well as at 
refrigeration conditions. The % assay was carried out in 
order to determine the degradation of drug and in turn 
shelf life. The assay procedure as well as method of 
analysis was same as that for the drug content.  
RESULT AND DISCUSSION 
Characterisation of drug: 
INH was characterised for identity and purity by 
determination of thermal behaviour of drug by DSC and 
FTIR spectra. The characteristic IR peaks observed for 
INH included NH stretch at 3346.61 cm
-1
,C-H aromatic 
ring stretch at 3027.38 cm
-1
, C-H stretch at 2857.64 cm
-
1
,C=O stretch at1724.42 cm
-1
, C=C stretch at 1573 cm
-1
 
andC-N stretch at1208.44 cm
-1
(Fig 1A).The melting 
endotherm of INH was observed at 171.94°C (Fig 1B) 
which conformed to the reported value (171-173ºC) 
thus, confirming its purity and identity. 
 
 
Figure 1:  A: FT-IR spectra of INH, B: DSC thermogram of INH 
High Performance Liquid Chromatography (HPLC) 
Analytical method: 
The calibration curve showed good linearity in the 
Beer’s law limit of 5-25 μg/mL in mobile phase with 
correlation coefficient (r
2
) of 0.9946 (Fig 2). The method 
was validated by different parameters which include 
precision (intra-day and inter-day precision), accuracy, 
limit of detection (LOD) and limit of quantification 
(LOQ). The percent relative standard deviation (% RSD) 
values of interday and intraday precision were found to 
be 1.18 and 1.39 for 5 μg/mL. The mean recovery (n= 3) 
was found to be 98.70% (% RSD =0.60) showing the 
accuracy of the method. Limit of detection (LOD) and 
limit of quantification (LOQ) was found to be 0.47 
µg/mL and 1.42 µg/mL respectively. 
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Figure 2: Calibration curve of INH by HPLC (*n=3, 
mean ± SD) 
Drug excipient compatibility studies: 
This study was carried out to check the interaction of 
drug and excipients. The FT-IR spectral analysis of INH 
showed the principal peaks of NH stretchat wave 
number of 3346.61 cm
-1
,C-H aromatic ring stretch at 
3027.38 cm
-1
, C-H stretch at 2857.64 cm
-1
,C=O stretch 
at 1724.42 cm
-1
, C=C stretch at 1573 cm
-1
 and C-N 
stretch at 1208.44 (Fig 3) confirming the purity of drug. 
The FT-IR spectra of binary mixture and physical 
mixture of drug with cholesterol, SL, Span 20 and 
Carbopol 934 showed no significant changes which 
indicated that there was no interaction between INH and 
other excipients. 
 
Figure 3: Compatibility studies of binary mixtures of 
drug and excipients (1:1 ratio) with 
A: cholesterol, B: Carbopol 934, C: Span 20, D: SL and 
E: physical mixture. 
Preliminary Stability studies: 
Solution state stability studies: 
Solution state stability studies of 1 % aqueous solution 
of INH revealed significant degradation with time. The 
results indicated that the degradation was strongly 
temperature-dependent with significant decrease in drug 
content (Table 2). INH was found to have maximum 
stability at refrigeration. Kakemiand co-workers had 
studied the degradation of INH in aqueous solution 
under aerobic conditions. Alkaline hydrolysis under 
aerobic conditions yields a mixture of isonicotinic acid, 
isonicotinamide and 1, 2 di isonicotinoyl hydrazine plus 
small amounts of unidentified products. Under anaerobic 
conditions isonicotinic acid and 1, 2 di isonicotinoyl 
hydrazine were the principal products. Hald found that 
INH underwent slow oxidation in aqueous solution. 
Pawelczyk and co-workers found that as long as 
conditions were kept anaerobic the decomposition of 
INH in the pH range 3-7 followed first order kinetics. 
They reported that 1% solution of the drug was 37 times 
more stable at pH 6 than at pH 3 
33
.Razak et al 
34 
reported that INH in solution form degrades 2 folds at 
40°C than that of the RT due to high humidity and 
temperature conditions leading to hydrolysis and 
oxidation. They also mentioned about degradation of 
INH solution due to light at both conditions, exposure to 
UV light as well as at room light. They discussed that 
INH absorbed photons at certain wavelengths and there 
is an increased in its energy which leads to INH 
decomposition. Also, it is reported that INH is stable at 
RT for more than 14 days in aqueous solution and more 
than 6 weeks when stored at about 4°C 
35
, thus justifying 
our findings. 
Solid state stability studies: 
The solid state stability of INH was investigated at RT, 
accelerated conditions and refrigeration for 1 month in 
stability chamber and evaluated for its drug content at 
weekly intervals and FT-IR spectra was recorded after 1 
month. The FT-IR spectra (Fig 4) of the drug kept in 
both amber and transparent vials at RT conditions and 
accelerated conditions showed a prominent peak of NH 
stretch at 3458.48 cm
-1
. Besides this the C=O peak was 
shifted from1663.66 cm
-1
 to 1659.80 cm
-1
. Bhutani et al
 7
 
confirmed that the degradation compound of INH due to 
photolysis showed peaks at 3432 cm
-1
 (NH); 1682 cm
-1
 
and 1660 cm
-1
 (C=O). This indicated that the 
degradation in solid drug at accelerated conditions and 
RT condition in amber and transparent vials was due to 
photolysis. Stets et al
 36 
estimated that the INH 
degradation occurs with a relevant participation of O2, 
with non-negligible contributions of both OH and H
+
. 
They also concluded that INH could be effectively 
degraded by UV-A radiation in TiO2-mediated 
photocatalysis and homogeneous photo-Fenton 
processes; both the processes allowed degradation 
around 80% of the initial pharmaceuticals content within 
60 min. Bhutani et al 
7
 reported that degradation of INH 
followed SRN1 type radical mediated chain reaction 
involving three steps. First step involves transfer of an 
electron to INH in the presence of light, leading to the 
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formation of a radical anion. The radical ion is assumed 
to disintegrate through a unimolecular process into a 4-
pyridoyl radical and hydrazine anion. In the second step, 
4-pyridoyl radical would abstract a proton from the NH2 
group of INH to form an anion of isoniazid and 
hydrazine. The nucleophilic attack by anion of isoniazid 
on 4-pyridoyl radical. Third step leads to radical anion 
that finally transfers an electron to INH to produce the 
end product (Isonicotinic acid). In the process, radical 
anion is released in first step, which continues to 
propagate the chain reaction. The drug kept at 
refrigeration did not show any significant changes in FT-
IR spectra as compared to drug, thus confirming that the 
solid drug was stable at refrigeration. The drug content 
of the solid INH at weekly intervals for 1 month (Table 
3) showed significant degradation at accelerated 
condition and RT conditions indicating that the drug was 
unstable in these conditions. Whereas, the drug was 
stable at refrigeration as no significant change in the 
drug content was observed. 
 
Figure 4: FT-IR spectra of drug A: at 0 days, B: in 
transparent vial at 30°C/75 %RH C: in amber coloured 
vial at 30°C/75, D: at 5°C amber coloured vial, E: at 
40°C/75%RH in amber coloured vial. 
 
Stability studies of INH cream: 
The INH cream was prepared and kept at accelerated, 
RT and refrigeration conditions. The results for drug 
content of cream showed significant degradation at all 
the three storage conditions. Maximum degradation was 
observed at accelerated conditions followed by RT and 
refrigeration. This confirmed that INH degradation is 
highly temperature dependent in presence of water. Lee 
et al
 37
 stated that the INH intravenous solution was more 
stable at refrigeration condition than that of RT, 
supporting the findings. This suggests storage of INH 
topical preparation at lower temperatures (Table 4). 
There was significant degradation seen even at 
refrigeration, this indicated that INH require additional 
protection from hydrolysis and oxidation. No literature 
was found regarding semisolid formulation of isoniazid.  
Table 3: Results of drug content of INH solution (*n = 3, 
mean ± SD) 
Condition Week %Assay 
 
40°C/75%RH. 
(Amber coloured bottle) 
1 102%±1.93 
2 90.35%±0.27 
3 80.39%±1.84 
4 75%±2.37 
 
30°C /65% RH 
(Amber coloured bottle) 
1 103%±1.82 
2 101%±2.60 
3 96%±2.70 
4 85.59%±1.65 
 
5°C 
(Amber coloured bottle) 
1 102%±1.11 
2 96.02%±1.24 
3 98.92%±2.67 
4 97.54%±1.44 
5 94.23%±0.32 
6 90.40%±1.21 
 
Table 4: Results of drug content of solid drug (*n = 3, 
mean ± SD) 
Condition Week %Assay 
40°C/75%RH 0 100%±0.49 
1 95.36%±1.45 
2 87.31%±1.40 
3 82.15%±128 
4 71.53%±0.47 
30°C /65% RH 
(Amber coloured bottle) 
0 100%±1.99 
1 98%±1.41 
2 95%±1.20 
3 89%±2.11 
4 83%±1.44 
5°C 
(Amber coloured bottle) 
1 102%±0.89 
2 100%±0.70 
3 101%±1.23 
4 99.58%±1.46 
5 98%±1.38 
6 99.37%±1.79 
 
Stability studies of INH plain gel: 
The INH plain gel was prepared and kept for stability 
studies for 1 month in amber coloured bottle. From the 
results obtained of stability of INH in solution state, 
solid state and in cream, it was confirmed that the drug 
was unstable at accelerated conditions. Hence the gel 
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formulation was stored at RT and refrigeration 
conditions. The results indicated that the drug in gel 
form degraded significantly at RT as well as 
refrigeration (Table 5). The extent of degradation was 
greater in gel than cream which was obviously due to 
higher water content in gels. These results suggested that 
carriers may aid in protection of INH from hydrolysis, 
oxidation and photodegradation. 
 
Table 5: Results of drug content of INH cream (*n = 3, mean ± SD) 
Condition Week % Assay 
40°C/75%RH. 
(Amber coloured bottle) 
0 98.25%±1.35 
1 84.55%±1.40 
2 66.62%±0.89 
3 54.62%±1.39 
4 49.46%±1.91 
30°C /65% RH 
(Amber coloured bottle) 
0 97.27%±1.61 
1 94%±1.49 
2 90.45%±1.38 
3 85.39%±2.10 
4 81.61%±1.44 
5°C 
(Amber coloured bottle) 
0 98.39%±1.50 
1 92.54%±2.18 
2 90.61%±1.47 
3 85.62%±1.18 
4 83.82%±1.33 
 
Stability studies of INH proniosomal gel: 
The results of stability studies of INH in cream and plain 
gel formulation indicated its high degree of instability. 
Hence further stability studies were conducted using 
proniosomes as carriers. The results for drug content of 
PNG at refrigeration conditions showed good stability as 
compared to RT. This indicated that INH was stable in 
PNG at refrigeration condition (Table 6). The greater 
stability of the drug in the PNG might be due to the 
protective barrier properties of proniosomes. Shukla and 
Tiwari 
38
 confirmed that PNG formulation prevents 
hydrolysis of encapsulated drugs. Mokhtar et al. 
39
 stated 
that liposomes and niosomes are dispersed aqueous 
systems and have a problem of degradation by 
hydrolysis or oxidation but there is no such condition 
with use of proniosomal gel. Hence PNG was selected as 
a carrier for topical INH preparation with storage 
condition at 5°C in amber coloured bottle. The reported 
literature also revealed that PNG is more stable at 
refrigeration conditions than at RT followed by 
accelerated conditions, thus supporting the findings 
18
. 
Selection of surfactant: 
The trial batches of proniosomes were prepared using 
different surfactants. The blank proniosomes prepared 
using Span 20, Span 60 and Span 80 with other 
excipients such as SL, cholesterol and ethanol were 
analysed for vesicle size as well as PDI. The 
proniosomes prepared using Span 20 showed least 
vesicle size as well as low PDI as compared to Span 60 
and Span 80as PDI >0.3 indicate heterogenicity of 
vesicles 
40
. The vesicle size is strongly influenced by the 
chain length of the surfactant with smaller chain length 
surfactants forming smaller vesicles. Span 20 (C12) 
41 
have shorter chain length as compared to Span 60 (C15) 
and Span 80 (C18). Hence Span 20 was selected among 
the other surfactants (Table 7). 
Table 6: Results of drug content of plain gel (*n = 3, 
mean ± SD) 
Condition Week % Assay 
30°C /65 % RH 
(Amber coloured 
bottle) 
0 97%±0.50 
1 91%±1.39 
2 85%±2.15 
3 71%±1.30 
4 65%±1.13 
5°C 
(Amber coloured 
bottle) 
0 103.23%±1.27 
1 98.33%±1.13 
2 86.47%±1.30 
3 82.99%±1.55 
4 74.11%±1.13 
 
Table 7: Results of drug content of proniosomal gel (*n 
= 3, mean ± SD) 
Condition Week % Assay 
30°C /65 % RH 
(Amber coloured bottle) 
0 101%±1.21 
1 98±1.34 
2 90.62±1.78 
3 86.14±2.19 
4 80.29±1.13 
5°C 
(Amber coloured bottle) 
0 101.74±1.28 
1 103.28±1.69 
2 101.19±1.27 
3 92.91±1.50 
4 95.57±1.67 
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Experimental design:  
Effect of 3 independent variables at 2 different levels on 
various responses was evaluated using Box-Behnken 
design. These independent variables included Span 20, 
cholesterol and SL with vesicle size and percent EE as 
responses. Based on 2 levels and one centre point, 15 
batches (F1-F15) generated by Design Expert Software 
(Design Expert 11, Stat-Ease, Minneapolis, MN) were 
prepared. The measured responses were used to 
construct 3D response surface plots to establish the 
relationship between variables and their interaction. 
Analysis of variance (ANOVA) was used to validate the 
design. 
1. Vesicle size: 
Vesicle size is an important evaluation parameter to 
prevent its aggregation and maintain stability of vesicles. 
Smaller the vesicle size greater is the stability of the 
vesicles and permeation through the skin barriers. The 
mean vesicle size (Y1) of all factorial batches of 
proniosomes was found to be between 1-9µm.The 
significant (p < 0.05) quadratic effect of Span 20 was 
found to be negative (Eq.2) which indicated that the 
increase in concentration of Span 20 (A) decreased 
vesicle size. This could be explained by the easier 
formation of the vesicle and/or better accommodation of 
the surfactant in the vesicle structure with increase in 
surfactant concentration (Shatabdi et al., 2010) 
42
. Also, 
pankaj et al 
43
 reported that increase in the concentration 
of surfactant increases the hydrophobicity and in turn 
decreases the surface energy of the vesicles thus 
decreasing the particle size. The significant (p < 0.05) 
quadratic effect of concentration of SL on vesicle size 
was found to be negative which might be due to 
increased hydrophobicity with increase in concentration 
of SL. Thus, decreases water intake in the vesicles which 
could lead to reduced vesicle size 
44
. A non-significant 
(p > 0.05) interaction was observed between all the other 
variables. The above hypothesis could be proved with 
the response surface plot (Fig 5). 
Y1 = 9.05 - 0.1539A + 1.19B - 0.3869C - 0.6720AB + 
0.5047AC + 1.28BC - 3.02A
2
 - 1.06B
2
 -3.41C
2
 (Eq.2)
 
 
Figure 5: Response surface curve plot for vesicle size (Y1) 
 
2. Entrapment efficiency: 
The EE of drug in any carrier system is an important 
parameter as it affects the amount of carrier required and 
also performance of drug delivery form. The EE (Y2) of 
all factorial batches of proniosomes was found to be 
between 88-98 %. The polynomial equation (Eq.3) 
indicated that concentration of Span 20 (A) had positive 
effect on EE (p<0.05). Since the non-ionic surfactant is 
the principal component responsible for the bilayer 
structure formation, an increase in surfactant 
concentration resulted in increase in EE. Increased 
concentration of surfactant could be forming more 
number of niosomes leading to higher entrapment
 31
. 
Besides this, it may also be proposed that the volume of 
the hydrophobic bilayer of the vesicles increases due to 
higher number of surfactant molecules getting 
interspersed in these bilayers leading to greater internal 
volume available for drug entrapment 
45
. In case of 
SL(C) increase in its concentration was found to 
increase entrapment up to a certain concentration 
followed by decrease in EE with further increase in 
concentration.This may be attributed to increased 
rigidity and hydrophobicity of the vesicles which 
restricts the entrapment of a hydrophilic drug like INH. 
Also, low solubility of the drug in SL could be the 
reason for decreased EE at higher concentrations of SL 
40
. All the other factors were found to have insignificant 
effect on EE (p > 0.05). The above hypothesis could be 
proved with the response surface graphs (Fig 6). 
Y2 = 98.06+2.97A-0.3788B-2.97C+0.4425AB-
0.7100AC-1.29BC+2.33A
2
+0.8087B
2
-2.79C
2
(Eq.3) 
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Figure 6: Response surface curve plot for Entrapment efficiency (Y2) 
 
Selection of optimised batch: 
The selection of optimised batch for PNG was done by 
making various trials with the goal of least particle size 
(1 - 9 µm) and highest EE (88 - 98 %). The selection of 
batch was done by numeric optimisation with 
desirability function. The constraints for vesicle size 
(Y1) was1-3µm and for EE (Y2) it was 98 %. Different 
optimised batches (3) given by software were prepared 
and analysed and one batch was selected based on the 
desirability function. The optimised batch consisted of 
Span 20 (A=3.576 g), cholesterol (B=0.395 g), and SL 
(C=0.1 g) with vesicle size predicted to be 2.747µm and 
EE predicted to be 98.58 % with desirability 1. Vesicle 
size observed was 2.27 µm and EE of 98.15 % with 
standard error of 1.82 for vesicle size and 0.25 for 
EE.Thus, the batch giving minimum vesicle size and 
maximum EE was selected as optimised batch. 
Evaluation of optimised proniosomes: 
Besides the two responses (Y1 and Y2) the optimised 
proniosomes were also evaluated for its ZP. The ZP of 
the optimised batch was determined by Zeta sizer and 
was found to be -5.40mV. Normally the ZP in the range 
of -25 to +25 mV is considered to be good and the 
formulation to be stable 
18
. The ZP outside the range is 
indicative of weak repulsive forces between the vesicles 
which causes aggregation and instability of the 
proniosomes. 
The optimised proniosomes were also evaluated by 
optical microscopy. The proniosomes were mounted on 
glass slides and viewed under a microscope (Make: 
Olympus, Model: DSZ 77) with a magnification of 40X 
for morphological observation after suitable dilution 
47
. 
The image (Fig 7) revealed that the proniosomes of INH 
formed from Span 20, cholesterol and SL was spherical 
in shape and no agglomeration or aggregation of the 
proniosomes was seen. 
 
Figure 7: Microscopic image of proniosomal gel. 
Evaluation of optimised proniosomal gel: 
The optimised proniosomes when dispersed in carbopol 
934 gel formed PNG. This optimised PNG was 
evaluated for various evaluation parameters such as in 
vitro release studies, ex vivo permeation studies, skin 
irritation studies and in vivo skin retention studies.
 
Table 8: Results of trial batches for selection of surfactant (*n = 3, mean ± SD) 
Batch Surfactant Vesicle size (µm) Polydispersibility index 
B1 Span 20 3.117±2.3 0.365±0.128 
B2 Span 60 4.309±3.8 1±0.01097 
B3 Span 80 8.080±2.4 1±0.153575 
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Table 9: Results of batches for optimization of formulation (*n = 3, mean ± SD) 
 
Table 10: Results of drug content of optimised 
proniosomal gel (*n = 3, mean ± SD) 
 
Week 
Refrigeration 
condition in amber 
coloured bottle 
Room temperature 
condition in amber 
coloured bottle 
% Assay  %Assay 
1 101.74±14 100.12 
2 103.28±17 98.36 
3 101.19±33 93.88 
4 92.91±12 89.11 
5 95.57±16 82.57 
6 97.33±22 78.19 
7 101.12±26 75.64 
8 99.67±23 70.16 
9 110.99±11 - 
10 97.37±32 - 
11 95.62±15 - 
12 91.30±17 - 
 
1. pH: 
The pH is an important evaluation as the drug shows 
degradation in acidic and basic environment 
7
. Also, 
acidic or basic pH may cause irritation on the skin. 
Hence the pH of the optimised PNG was determined by 
digital pH meter in ambient temperature in triplicate. 
The pH of the optimised PNG was found to be 7.3±0.19. 
These results indicated that the optimised PNG was of 
neutral pH. As the optimised PNG showed neutral pH, 
the pH dependent degradation of drug was avoided. 
2. Viscosity: 
Viscosity of the optimised PNG was determined by 
Brookfield digital viscometer at ambient temperature 
and at fixed rpm (20). The viscosity of the optimised 
PNG was found to be 60250±250 cp and optimised 
proniosomes was found to be 628±33 cp. Viscosity of 
optimized PNG was due to the concentration of 
Carbopol 934 (5%) present in formulation. The viscosity 
of 5 % Carbopol gel was found to be 59650±409.26 cp. 
This indicated that incorporation of proniosomes into the 
Carbopol gel increases the viscosity of the formulation. 
This might be due to proniosomes being incorporated 
into the gel matrix of the Carbopol gel. The results 
indicate that the optimised PNG has adequate viscosity 
and hence will have good residence time on skin as well 
as good spreadability.  
3. Spreadability: 
The spreadability of optimised PNG was determined by 
texture analyser with trigger load of 0.5 g and test speed 
of 1 mm/sec by measuring force required to spread the 
formulation. This property depends onhardness of PNG, 
as hardness increases spreadability of PNG decreases. 
The hardness value of the optimised PNG was found to 
be 37.82 g which indicate good spreadability of the 
formulation. The spreadability of the formulation is 
inversely proportional to the viscosity. Hence it could be 
concluded that the formulation is having good 
spreadability and will evenly distribute on skin surface 
covering larger skin surface area. 
4. In vitro release studies and ex vivo permeation 
studies: 
The In-vitro release profile of INH from the optimised 
PNG as well as INH plain gel was investigated for 6 h 
using cellophane membrane by Franz diffusion cell at 
37°C in phosphate buffer pH 5.5. In-vitro release studies 
will be predictive of In-vivo product behaviour. The 
results (Fig 8A) indicated that during the first hour, the 
drug release was slow probably because of the slow 
diffusion of drug from vesicles then it increased till the 
6
th
 hour. The % of INH released from optimised PNG 
was found to be 98.10±1.28% and from plain gel it was 
Std 
 
Factor 1 
 
 
Factor 2 
 
 
Factor 3 
 
Response 1 
Y1 
Response 2 
Y2 
A: Span 20 
 
B: Cholesterol 
 
C: Soya 
Lecithin 
Vesicle Size 
 
Entrapment 
Efficiency 
g g g (µm) % 
F1 0.9 0.1 0.25 2.535±2.4 92.24±1.26 
F2 3.6 0.1 0.25 5.191±3.5 97.18±1.37 
F3 0.9 0.4 0.25 6.087±2.125 91.78±2.12 
F4 3.6 0.4 0.25 6.055±3.348 98.49±2.13 
F5 0.9 0.25 0.1 5.211±2.11 91.15±1.30 
F6 3.6 0.25 0.1 2.274±2.218 98.64±1.17 
F7 0.9 0.25 0.4 1.961±1.129 88.67±1.32 
F8 3.6 0.25 0.4 1.043±2.129 93.32±1.4 
F9 2.25 0.1 0.1 4.230±1.35 98.13±1.3 
F10 2.25 0.4 0.1 3.23±2.495 98.77±1.9 
F11 2.25 0.1 0.4 2.355±3.5 92.74±1.07 
F12 2.25 0.4 0.4 7.491±2.8 88.22±1.59 
F13 2.25 0.25 0.25 9.011±1.7 98.07±1.21 
F14 2.25 0.25 0.25 8.47±2.1 97.99±1.72 
F15 2.25 0.25 0.25 9.66±1.92 98.12±1.52 
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found to be 71.28±1.66 % after 6 h. Span 20 has a 
relatively lower phase transition temperature (16) and 
the proniosomes get converted to niosomes due to 
hydration by skin moisture at skin temperature. This also 
makes the vesicle bilayers more fluid and leaky resulting 
in release of the drug 
30
. Rahman et al 
32
 stated that 
niosomes exhibit an alkyl chain length-dependent 
release and the higher the chain length, the lower the 
release rate. As Span 20 has smaller chain length 
relatively faster release was observed from optimised 
PNG. Also, Shehata et al
 48
 reported that negatively 
charged proniosomes showed better release of the drug 
than that of the neutral or the positively charged 
proniosomes. This could be another possible explanation 
for higher release of drug from the proniosomes, as the 
ZP of the proniosomes was found to be negative. 
Ex vivo permeation studies help in predicting in vivo 
permeation behaviour of the drug. Ex vivo permeation 
studies were performed similar to that of release study 
by replacing cellophane membrane with the 
subcutaneous skin of male albino rat. The results (Fig 8 
B) showed the percentage drug release of INH through 
rat skin (phosphate buffer pH 5.5). The results showed 
85±1.53 % and 56.36±1.69 % permeation of the drug 
from the rat skin within 6 h with flux of 293.80 and 
190.55 μg/cm2/h for the optimised PNG and plain gel 
respectively. Ruela et al 
32
 stated that drugs with low 
melting point (<200 ºC), which is related to an 
appropriate solubility in water and oils is required to 
achieve a high concentration gradient and increase the 
diffusion force across the skin. INH has a melting point 
171ºC (<200 ºC) which contributes to the increased 
permeation of the drug through the skin 
32
.PNG 
permeates through transcellular route (a polar pathway) 
by swelling of the intracellular protein matrix, alteration 
of protein structure within the corneocytes which 
enhances drug delivery 
49
.Prasad et al 
30
, reported that 
increased permeation flux may be due to the non-ionic 
surfactant present in it, which modifies the structural 
composition of stratum corneum and increases the 
thermodynamic activity of the drug as well as skin 
vesicular partitioning. Also, presence of SL in the 
formulation acts as permeation enhancer besides its role 
as vesicle stabilizer. The absence of surfactant may be 
the reason for less permeation in plain gel as compared 
to optimised PG. Also, the PNG has the composition 
similar to stratum corneum lipids which enhances its 
penetration, once applied to the skin surface in contrast 
with that of plain gel which deposits the drug over the 
surface of the skin, being hydrophilic in nature. Ibrahim 
et al
 50
 also stated that the release of the drug from PNG 
is more than that of its permeation indicating the barrier 
properties of the skin. This justifies the decrease in 
permeation of the drug through animal skin as compared 
to the release of the drug from PNG. 
 
 
Figure 8: A: The in vitro release studies and B: ex vivo permeation of optimised proniosomal gel 
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5. In vitro skin irritation studies: 
The in vitro skin irritation studies were carried out on 
male albino Wistar rats with standard approved protocol. 
The skin was observed for any visual change such as 
erythema at 24, 48 and 72 h after the application of the 
optimised PNG to the shaved rat skin. The results (fig 9) 
showed that the rat skin to which standard irritant 
(formalin 0.8 %) was applied showed score 4 (extreme 
erythema). There was no difference in skin score of 
control rat (no application of formulation or irritant) and 
the rat skin on which optimised PNG or blank PNG was 
applied. The mean erythemal score for rat on which 
optimised formulation was applied was 0, which 
indicated absence of irritation to the rat skin. This is 
points to the safety and non-irritant nature of the 
formulation. 
 
Figure 9: Skin irritation studies results showing A: 
control, B: blank proniosomal gel, C: standard irritant D: 
optimised Proniosomal gel formulation. 
6. In vivo retention studies: 
In retention study, the amount of INH accumulated into 
the viable skin after 3 h of applying the optimised PNG 
in vivo to the rat skin was recorded. The result showed 
that 436±12 µg of drug was retained in the skin.  The 
higher amount of drug retained in the skin could be 
contributed to small vesicle size, the interaction between 
optimised PNG having similar lipidic composition as 
that of stratum corneum lipids resulted into providing a 
deposit effect of the drug in the skin which may prolong 
the drug residence time. Moreover, surfactant present in 
the optimised PNG may be responsible for the higher 
drug retention which may also integrate as well as mix 
with skin lipids to loosen their structure by disturbing 
the lamellar arrangement of the lipids
31
. The ideal 
physicochemical properties of a drug selected for 
cutaneous administration are low molecular weight 
(<600 Da) 
32
. The molecular weight of INH is 137.05 
Da, which is much less than the ideal requirement which 
in turn suggested increased retention of drug into the 
skin. Apart from these facts the results of in vitro and ex 
vivo release studies showed that there is decrease in drug 
release when used rat skin than that of cellulose 
membrane which suggested that the various barriers 
present in the skin retain the drug for the longer time. 
Also, Udasi et al
51
 stated that PNG shows sustained and 
control release by depot formation. These all factors 
together contribute to higher amount of drug retained in 
the skin. 
7. Stability studies: 
The formulation was kept for stability study at 
refrigeration, RT conditions for 3 months. The optimised 
PNG was analysed for drug content after every week by 
HPLC as analytical method. The results (Table 9) of 
drug content showed degradation in the sample kept at 
RT in amber coloured bottle as well as in transparent 
bottles. The sample kept at refrigeration conditionsin 
amber coloured bottle showed insignificant degradation. 
This indicated that the formulation kept at refrigeration 
conditions is stable. The results showed that the drug is 
stable in optimised PNG formulation atrefrigeration 
conditions. According to Udasi et al 
51
, PNG decreases 
the hydrolysis of the drug and also decreases the 
problem of physical instability like aggregation, leakage, 
sedimentation during storage. The drug is entrapped 
inside the bilayer, thus making it less exposed to the 
external environment like oxygen, light and water. This 
makes the drug stable against hydrolysis, oxidation and 
photodegradation. This might be the reason for stability 
of the drug in the provesicular approach (PNG). Also, as 
reported before the ZP of the formulation being very 
less, it in turn contributes to the increased stability of the 
formulation. Various literature reports that PNG is more 
stable at refrigeration conditions than that of the room 
temperature thus supporting our results
30,31,32,52,53
. 
CONCLUSION 
Oral therapy of anti tubercular drugs for treatment of 
cutaneous tuberculosis is beset with problems related to 
inadequate quantity of drug reaching the peripheral site. 
No literature was found regarding topical therapy for 
cutaneous tuberculosis hence there was a need to 
develop a topical preparation to enhance the efficiency 
of current therapy. The current research provides an 
alternative drug delivery of INH to the skin affected by 
tuberculosis by provesicular approach. The PNG of INH 
was formulated which showed high release, permeation 
through the skin as well as significant retention in the 
skin. Also, there was insignificant degradation of the 
drug in the formulation when stored at refrigeration 
conditions indicating stability of the drug in the 
formulation. 
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